Hino, Japan

Naoji Umemoto


Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 256(Granted Patents)


Company Filing History:

goldMedal6 out of 1,588 
 
Teijin Limited
 patents
silverMedal1 out of 1 
 
Hidematsu Hirai
 patent
bronzeMedal1 out of 832,912 
Other
 patents
where one patent can have more than one assignee

Years Active: 1982-1991

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Naoji Umemoto: Innovator in Cytotoxic Antibody Conjugates

Introduction

Naoji Umemoto is a prominent inventor based in Hino, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of cytotoxic antibody conjugates. With a total of 6 patents to his name, Umemoto's work has the potential to impact cancer treatment and immunotherapy.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Cytotoxic antibody conjugates and a process for preparation thereof." This patent describes a conjugate that possesses cytotoxicity, achieved by covalently binding a polymer with cytotoxic substances linked to its side chains and a reactive group at its terminal to an immunoglobulin or its fragment. This innovative approach allows for selective binding to specific antigens present on target cells, enhancing the effectiveness of cancer therapies.

Career Highlights

Throughout his career, Naoji Umemoto has worked with notable companies, including Teijin Limited and Hidematsu Hirai. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Umemoto has collaborated with esteemed colleagues, including Takeshi Hara and Yoshinori Kato. These partnerships have fostered innovation and advancement in his research endeavors.

Conclusion

Naoji Umemoto's contributions to the field of biotechnology, particularly through his patents on cytotoxic antibody conjugates, highlight his role as a significant inventor. His work continues to pave the way for advancements in cancer treatment and immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…